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ARVC: Imaging Diagnosis Is Still in the Eye
of the Beholder*
David A. Bluemke, MD, PHD
Bethesda, Marylandi
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rArrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D) is both a fascinating and
potentially lethal condition. The peculiar ten-
dency of this cardiomyopathy to preferentially
affect the right ventricle (RV) is very unique.
Failure to accurately diagnose the disease places
See page 282
relatively young individuals at risk for fatal arrhythmia.
Despite the extremely rare nature of this disease in the
U.S., the condition accounts for a disproportionately
high percentage of referrals to cardiac magnetic reso-
nance (CMR) centers. In some centers, up to 50% of
nonischemic cardiomyopathy requests are for the pur-
pose of “ruling out” ARVC/D.
The interaction between CMR and ARVC/D
began in 1989, when Wolf et al. (1) indicated that
“MRI [magnetic resonance imaging] showed dys-
plastic lesions in the RV wall presenting typically as
fat-like high signals contrasting with the normal
myocardium.” In 1993, Auffermann et al. (2) de-
scribed both global and regional functional abnor-
malities of the RV. Approximately one-third of
patients had fatty replacement of the RV wall that
was confirmed by biopsy. In 1994, Blake et al. (3)
described CMR features in ARVC/D, indicating
that “the essence of the diagnosis depends on the
visualization of fat or extreme thinning in the
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all of the right ventricle.” These 3 early articles set
he direction for the CMR community to develop
mproved methods for ARVC/D diagnosis. In par-
icular, significantly improved spatial and temporal
esolution would be needed to observe and charac-
erize wall motion abnormalities and ventricular
orphology in ARVC/D.
The first patient with proven ARVC/D that I
ncountered in the early 1990s was typically bizarre
n CMR manifestations: a boggy, dysfunctional RV
as present, whereas the left ventricle was essen-
ially normal. Several CMR issues were also appar-
nt: 1) the image quality was poor; patients with
RVC/D frequently have electrical abnormalities
hat cause CMR gating to fail; 2) long-axis cine
mages used the fast gradient echocardiography
FGRE) technique; in the failing RV, blood signal
as low (owing to in-plane flow) with FGRE,
aking it difficult to distinguish the RV wall; and
) “fat” T1-weighted images were blurry and hard
o interpret because of poor blood suppression and
otion abnormalities (4). Because of these techni-
al problems, CMR physicians have had difficulty
nding reliable CMR features to reliably diagnose
RVC/D. Sophisticated clinical cardiologists be-
ame appropriately wary of relying on CMR for
iagnosis of ARVC/D. A survey of patients at
ohns Hopkins University showed that nearly 70%
f outside patients referred with a diagnosis of
RVC/D were eventually ruled out for the condi-
ion, and CMR was the most frequent cause of the
ncorrect diagnosis (5). A study led by Dr. Frank
arcus at the University of Arizona illustrated the
roblems with CMR technology used in the late
990s (6). In that study, CMR was incapable of
eliably demonstrating high-signal–intensity fat in
atients with ARVC/D. However, RV enlargement
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289was a quantitative feature that was proven to be
diagnostically useful.
The diagnostic criteria for ARVC/D were ini-
tially established in 1994 (7). These “task force”
criteria indicated that a combination of various
imaging, electrocardiography, and clinical and
pathologic findings should be used to formulate a
final diagnosis of the condition. The imaging com-
ponents of the task force criteria were unfortunately
vague and qualitative: RV dilation was either “se-
vere” or “mild,” with “reduced” ejection fraction.
Wall motion abnormalities were “severe” or “mild.”
These terms left much to the imagination of the
imaging diagnostician. To make matters worse,
CMR physicians found that minor regional con-
traction abnormalities occur even in the normal RV
(8). Distinguishing normal from abnormal under
these conditions clearly depended on the expertise
and experience of the CMR physician. Because
ARVC/D is so rare, the experience of physicians at
most CMR centers is usually a handful of
ARVC/D cases accumulated over many years.
Beginning in 2001, Marcus et al. (9) initiated the
North American ARVC/D Registry. In particular,
Dr. Marcus recognized the limitations of qualitative
ARVC/D criteria and sought to use the registry
findings to derive quantitative standards for diag-
nosis. The core laboratories in the registry measured
RV volumes and ejection fraction. In affected pro-
bands, CMR showed moderately or severely re-
duced ejection fraction (45%) in 32% of patients,
whereas fractional area change (FAC) by echocar-
diography was abnormal (26%) in only 16% of
patients (9). A normal ejection fraction was present
in 34% of probands by CMR, but normal FAC was
present in 58% of patients. These results suggested
the potential for improving the diagnostic task force
criteria by using cutoff values determined from
registry data.
In 2010, Marcus et al. (10,11) led an interna-
tional panel to propose modifications to the
ARVC/D task force criteria. The modification has
several purposes. One of the most important mod-
ifications is to facilitate diagnosis in first-degree
relatives who often have incomplete expression of
the disease. If a first-degree family relative has
proven ARVC/D, the proposed imaging criteria
will now require only “mild global dilatation or
reduction in RV ejection fraction with normal LV
[left ventricular] or mild segmental dilatation of the
RV or regional RV hypokinesis.”
A second important modification is quantitative
metrics for ARVC/D diagnosis. For CMR, thesemetrics were based on comparison of North Amer-
ican ARVC/D registry probands with normal vol-
unteers. Normal volunteers for CMR were obtained
from a multicenter study, the MESA (Multi-
Ethnic Study of Atherosclerosis) trial (12). For
derivation of the modified task force criteria
(10,11), RV metrics from 462 normal MESA
participants were compared with 108 probands in
the North American ARVC/D registry. From that
comparison, metrics for major criteria were targeted
to achieve approximately 95% specificity. Cutoffs
that achieve high specificity invariability result in
low sensitivity. For major criteria (RV ejection
fraction 40% or RV end-diastolic index 110
ml/m2 for men and 100 ml/m2 for women), the
ensitivity of CMR was much lower (68% to 76%)
han specificity (90% to 98%) by committee deci-
ion. For minor criteria (RV ejection fraction45%
r RV end-diastolic index100 ml/m2 for men and
90 ml/m2 for women), lower specificity of the
CMR was achieved (85% to 97%), but sensitivity
was correspondingly greater (79% to 89%). For
both major and minor criteria, a regional wall
motion abnormality also needs to be present. Thus,
the proposed modified task force criteria not only
defined new cutoff points for abnormality in
ARVC/D but also tested these cutoff points in
comparison with those from a large, established
database.
There are 2 main weaknesses of the modified task
force criteria for CMR. First, quantification of the
RV by CMR has substantial observer variability and
is pulse-sequence dependent (13). Measurement
variability is less than 10% for readers analyzing
thousands of RVs (14) but is probably 10% to 20%
in clinical practice. Also, cutoff values for ARVD
criteria were derived from the MESA study that
used the FGRE technique and studied an older
population (mean age 60 years). Recently Chahal et
al. (14) determined that although ejection fraction
did not vary by age in the MESA study, end-
diastolic volume decreased approximately 4.6% per
decade in older individuals (ages 45 to 84 years).
This raises the possibility that cutoff values for
end-diastolic volume in the revised criteria would
be more specific in young individuals if they were
slightly higher. Unfortunately, the relationship of
age to end-diastolic volume for individuals younger
than 45 years of age is unknown. Second, the
modified CMR criteria still require a subjective
feature: a regional wall motion abnormality must be
present in addition to quantitative metrics of RV
enlargement or decreased ejection fraction. The
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 3 , 2 0 1 1
M A R C H 2 0 1 1 : 2 8 8 – 9 1
Bluemke
Editorial Comment
290modified CMR criteria do not specify the presence
of RV aneurysms or segmental dilation as did the
original criteria. However, both aneurysms and
segmental dilation will result in a regional area of
akinesia or dyskinesia in the modified criteria.
The study by Vermes et al. (15) in this issue of
iJACC is particularly interesting. The study repre-
sents an unusual opportunity to determine the
impact of the modified task force CMR criteria on
ARVC/D diagnosis at a single center. As expected
by the design of the modified criteria, the specificity
of CMR diagnoses by Vermes et al. (15) was
substantially improved for both major (94% speci-
ficity) and minor (96% specificity) criteria. How-
ever, increased specificity is unavoidably accompa-
nied by reduced sensitivity: Vermes et al. (15)
showed CMR sensitivity of only 40%.
The results of Vermes et al. (15) raise 2 major
questions. First, will patients be adversely affected
by the modified task force criteria? Does a sensitiv-
ity of 40% also mean that 60% of affected patients
will be “missed”? There are several considerations in
this regard. First, Vermes et al. (15) observed only
10 patients with ARVC/D; therefore, the confi-
dence limits of their stated 40% sensitivity are large
(and are not specified by the investigators). The
modified task force diagnostic criteria are based on
a larger, multicenter sample of 44 patients (9) and
are likely to be more “accurate” in this regard.
Second, the 6 of 10 patients “missed” by CMR were
not in fact “missed.” These patients were identified
based on non-CMR task force criteria, such as
abnormal electrocardiograms or echocardiograms.
The investigators raised doubts as to whether the
modified task force criteria have successfully “im-
proved the sensitivity for identifying patients with
ARVC.” I believe the investigators’ doubts in this
regard are unfounded. First, they did not appear to
use all of the modified task force criteria but rather
just the modified CMR criteria. A central tenant of
ARVC/D diagnosis is that multiple criteria must be
used. Second, the modified task force criteria did
not primarily seek to improve sensitivity overall but
rather to improve sensitivity especially for the diag-
nosis of familial disease (10,11). The investigatorsrhythmogenic dysplasia of the right ease: MR imagingHas the second major goal of the modified task
force criteria been achieved (i.e., avoid relying on
“subjective criteria for assessing ventricular structure
and function . . .”)? The answer is probably “no.”
The subjective criterion of a wall motion abnormal-
ity remains as a gatekeeper that must be present
before defining the presence of a low ejection frac-
tion or dilation of the RV. Low ejection fraction or
degree of RV dilation simply determines if CMR
classifies the findings as major or minor.
Vermes et al. (15) showed the complexities of
identifying a wall motion abnormality and the
impact on diagnosis. For example, they classified
microaneurysms as present and contributing to
ARVC/D diagnosis in the original criteria but not
in the modified criteria. Technically, the original
task force criteria never referred to microaneurysms
but instead specified “aneurysms.” Subjectively, is a
“microaneursym” the same as an “aneurysm”? More
importantly, the quantitative CMR metrics pro-
posed in the modified task force criteria will only be
useful if: 1) the CMR laboratory develops its own
standards for normal subjects; and 2) those normal
metrics are the same as previously reported by
Tandri et al. (12) for the MESA study. If the CMR
laboratory derives different standards for normal,
then that laboratory will need to apply a correction
factor to the modified task force CMR criteria.
I applaud the efforts of Vermes et al. (15) to
tackle this difficult subject of ARVC/D interpreta-
tion. Unfortunately, ARVC/D diagnosis by CMR
and other imaging modalities remains somewhat
subjective, especially for identification of early dis-
ease. An expert imaging “eye” for diagnosis is
helpful, but expertise is difficult to achieve because
ARVC/D is extremely rare. In this respect, diag-
nostic confidence can be substantially improved by
using multiple diagnostic task force criteria rather
than reliance on any single imaging modality.
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